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Abstract
Objective: The objective of this selective EBM review is to determine whether or not treatment
with topical glyceryl trinitrate is effective in reducing elbow pain in patients with lateral
epicondylitis.
Study Design: Review of two English language randomized controlled trials and one primary
study published 2003, 2009, 2011.
Data Sources: Two double blind randomized controlled and one prospective comparison study
comparing the effectiveness of gylceryl trinitrate to placebo in the treatment of pain related to
lateral epicondylitis, found using PubMed, EBSCOhost, and CINAHL Plus.
Outcome(s) Measured: The outcome studied was patient self-rated elbow pain at rest, pain with
activity, pain at night, and local epicondylar and tendon tenderness, measured with Maudsley’s
test (newtons) with dynamometer and wrist extension mean peak force, ORI-TESTS.
Results: Paoloni et al (2003) showed pain and tenderness in 81% (35 of 43) patients in the GTN
group were asymptomatic with activities of daily living, compared to 60% (26 of 43) in the
placebo group. (p=0.005). The 2009 trial by Paoloni et al was inconclusive due to
discontinuation at 8 weeks due to insignificant findings. The prospective study by McCallum et
al in 2011 was inconclusive, showing no difference between the GTN group and placebo group
at 5 years post treatment.
Conclusions:
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INTRODUCTION
Lateral epicondylitis, more commonly known as tennis elbow, is a chronic, inflammatory
disorder of the extensor carpi radialis muscle attachment to the lateral prominence of the
humerus, the epidondyle. It is due to overuse or repetitive movement of the forearm, such as the
motion used when playing tennis, or when lifting heavy loads with the forearm pronated, or with
grasping. It is characterized by pain and tenderness to palpation over the epicondyle. The muscle
attachment over the epicondyle degenerates, causing the pain. It is often described clinically as a
dull aching pain, which interferes with activities of daily life due to inability to fully use the
affected arm. It commonly occurs in patients 30 – 50 years of age.1
To physician assistants who practice in general medicine and in musculoskeletal
specialties, this is very common injury seen. It is seen between 1-3% of adults (3.2-9.6 million)1,
and leads to many visits and decreased quality of life for patients. The economic burden on the
health care system and on the patients was not estimated in any academic sources. However,
with an average healing time of 18-24 months, it can be predicted that there are many hours lost
from work.
Lateral Epicondylitis is a well-known and studied pathology. The mechanism of injury,
as discussed above, is repeated stress to the tendon overlying the epicondyle, leading to
degeneration and pain for the patient. Symptoms include morning stiffness, point tenderness, and
pain with movement and gripping. It is a chronic condition, meaning that the symptoms last for
greater than three months.1 It decreases quality of life for patients, who have pain with
movement of the affected elbow for many months. What is unknown about this condition is the
most effective treatment, as there is no agreed upon treatment. There are many options, with

Chartier, GTN 2
physical therapy being the most prominent. Also unknown, and relevant to this review, is the
exact mechanism of action of glyceryl trinitrate.2
Most patients are indeed referred to PT, as this has yielded beneficial results, and is the
mainstay treatment. However, many patients continue to complain about the chronic pain, and
look for other options, if only for relief. These include NSAIDs, braces, corticosteroid injection,
eletro-stimulation, surgery, and RICE (rest, ice, compression, elevation.)
The method proposed and studied by this particular review is treatment with topical
glyceryl trinitrate (GTN) patches. This transdermal patch is used in conjunction with physical
therapy, in hopes of increased nitrous oxide and blood flow to the area, allowing healing of the
degenerated tendon. These patches have been shown effective in other tendonopathies. This
treatment method is being study due to its non-invasiveness for a very common medical
problem.2
OBJECTIVE
The objective of this systematic review is to determine whether or not treatment with
glyceryl trinitrate is effective in reducing pain in patients with lateral epicondylitis.
METHODS
Criteria: In order to answer the above question, this review focuses on a population over
the age 18, with a diagnosis of lateral epicondylitis. The interventions that were considered
include treatment with GTN transdermal patch verses a placebo. The outcomes measured
included patient rated pain at rest, with activity, and at night. The studies that are included are
two RCT’s and one primary study, all of which met above parameters.2,3,4
Data Sources: The sources used for this review came from a search of databases looking
at English language articles with the key words “lateral epicondylitis” and “glyceryl
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trinitrate.”All articles were published in peer-reviewed articles, and were selected based on
relevancy to the question asked, and if they included patient oriented outcomes that matter
(POEMS). The search was done via PCOM library access to PubMed, EBSCOhost, and
CINAHL Plus. Inclusion criteria for studies included randomization, double blind, and placebo
control. A trial was excluded if it was published greater than 15 years in the past, patients who
had an acute injury, or if a patient was under 18 years of age. Statistics used in these three trials
were Relative Risk Reductions (RRR), Absolute Risk Reduction (ARR) Numbers needed to treat
(NNT) and P-values.

Study

Type

#Pts Age
Inclusion
(years) criteria

Paoloni Double
(2003)4 blind
RCT

86

>18

Murrell Double
(2009)5 Blind
RCT

154

18-70

Patient over
the age of 18
who had
diagnosis of
chronic
lateral
epicondylitis

Exclusion
criteria

W/D

Tendonosis 8
< 3 month,
pregnancy,
Sx or
dislocation,
distal
neuro
signs, or
steroid
injection in
last 3 mo
Adults 18-70 BMI >38,
18
with dx of
regular
lateral
oral/topical
epicondylitis, analgesia,
who scored > steroid
4 on visual
injection in
1-10 pain
last 3 mo,
scale
work comp
cases,
pregnancy,
previous

Interventions
¼ of
5mg/24hour
Nitro-dur
patch

Orthoderm
0.72mh/24hr
Othroderm
1.44mg/24hr
Orthoderm
3.6mg/24hr
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GTN use,
cardiac dz,
upper limb
injury hx

Paoloni Primary
et al
(2009)2

58

>18

Patient over
the age of 18
who had
diagnosis of
chronic
lateral
epicondylitis

Tendonosis
< 3 month,
pregnancy,
Sx or
dislocation,
distal
neuro
signs, or
steroid
injection in
last 3 mo

Follow
up of
RCT
that
had 12
W/D

¼ of
5mg/24hour
Nitro-dur
patch

OUTCOMES MEASURED
All outcomes measure in these three studies reviewed are POEMs. The major outcomes
studied included patient rated elbow pain at rest, pain with activity, at night, and local
epicondylar/tendon tenderness. The patients, using questionnaires, rated these categories. Data
was collected from the surveys and further analyzed. The major measurement used in all three
studies was ORI-TETS, or the Orthopedic Research Institute Tennis Elbow Testing System.
This test is designed to objectively measure force generated with a simulated chair pickup test.5
Results were analyzed by statistical software (Sigmastat 2.0) by way of the Mann-Whitney rank
sum test to compare the differences within groups. Significant findings were defined with P
values of 0.05 or less. Patients rated safety and tolerability, with headaches and a dermatitis rash
being a major side effect. EDIT
RESULTS
All of the studies reviewed had patients who were previously diagnosed with lateral
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epicondylitis, and had agreed to follow up for the allotted time. Table One shows the
demographics for the patients included in all three studies. The data was presented in
dichotomous form for the two RCTs studied (Paoloni, Appleyard, Nelson, Murrel 2003; Paoloni
Murrell, Burch, Ang 2009), and in continuous form that was converted to dichotomous in the
primary study (McCallum, Paoloni, Murrell 2011).
In the RCT by Paoloni et al. (2003, Am Journal of Sports Medicine), 86 patients were
selected for the trial, split evenly into 43 GTN and 43 placebo patients. In the GTN group, 5
dropped out due to side effects (headache), 2 dropped out at the 2 week interval with no reason
given, and 1 dropped out due to work related injury. This resulted in 35 patients in the GTN
group who completed the 6-month trial. The authors reported that 81% (35 of 43) patients in the
GTN group were asymptomatic with activities of daily living, compared to 60% (26 of 43) in the
placebo group. A chi-square analysis was done comparing outcomes between the groups that
showed the GTN group had a significantly increased (p=0.005) chance of being asymptomatic by
week 24 of the trial. In regards to pain, tenderness, and mean peak force, a Mann-Whitney rank
sum test was performed, all showing benefit for the GTN patients.2

Table 2. Paoloni et al. (2003). Effects of Gtn therapy vs placebo on patient rated elbow pain.
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Pain was decreased most at week 2 of the study (p=0.002), tenderness was measured at
week 6 and 12, each with improvement and (p=0.02), and peak force at weak 24 was increased
(p=0.03). According to the journal, “at 6 months, 81% of treated patients were asymptomatic
during activities of daily living, compared with 60% of patients who had tendon rehabilitation
alone.” This gives us the Control event rate (CER) of 60%, for the patients with the placebo
patch, and an Experimental event rate (EER) of 81%. Relative risk reduction (RRR) was
calculated at 35%, absolute risk reduction at 21%, and numbers needed to treat (NNT) was 5.
The NNT shows that a practitioner needs to treat 5 patients who have tennis elbow with GTN in
order to have 1 patient show benefit.2
The most clinically significant side effects reported were headache in 63% (27/43), and
dermatitis rash in 21% (9/43). The placebo group had 58% (25/43) report headache.2
Paoloni was also involved in an RCT with the British Journal of Sports Medicine. In this
RCT (Paoloni et al., 2009), used intention to treat analysis of 154 patients, including 18
discontinued patients (3 dropped from placebo group, 3 from 0.72mg, 4 from 1.44mg, 8 from
3.6mg). They compared different strengths of GTN, namely OrthoDerm 0.72mg/24h (38
patients), 1.44mg/24h (30 patients), and 3.6mg/24h (36 patients) with placebo (32 patients). The
study showed significant improvement in elbow pain with activity at week 8 with the 0.72mg/24
h verses placebo (P=0.04). The authors discontinued the trial after week 8 due to lack of other
significant results. This trial had a CER of 88%, EER of 91%, RRR was 3%, ARR was 3% and
NNT was 34 in order to improve 1 patient’s symptoms.3
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The authors mention headache and dermatitis rash as clinically significant side effects for
treatment with GTN patches, with effects increasing as the dose was increased. Overall, 7 of the
GTN patients were discontinued due to severe headache (17%).3
The third study reviewed for this paper was a five-year prospective comparison. There
were 58 patients who had taken part in the original RCT of 6-month duration: 33 men and 25
women, with a mean age of 58 (range 40-78). At 5 years after discontinuation of treatment, the
results of treatment with GTN verses that with placebo (both with PT) were compared, and found
to be equally effective. Analysis was performed on patient-rated pain, and there were significant
improvements in both placebo and GTN groups compared with week 0 of the initial RCT.
However there was no significant difference in patient pain between the placebo and GTN
groups for activity pain (p=0.24), rest pain (p=0.16), or night pain (p=0.16) at 5 years. Similarly,
there was no significant difference in the prevalence of pain with activity (p=0.43) at rest
(p=0.24) or at night (p=0.26). There were also no significant differences in the prevalence of
lateral epicondylar tenderness (p=0.52) or in tenderness severity (p=0.16). The P-values here are
evident of non-significant data between the groups, showing no benefit of using GTN patches as
therapy.4
DISCUSSION
After review of the results as presented above, it is important to compare and contrast
efficacy, safety, and real life application of the glyceryl trinitrate for tennis elbow. It does not
appear that there are many insurance issues, as there were none listed. GTN patches can be
gotten generically, and use similar compounds found in nitroglycerin used for cardiac ischemia.
Availability in the U.S. would not be a limitation on treatment with GTN.
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It is evident that treatment with topical GTN patches has benefit on pain and tenderness
for the patient, but only in a short term follow up of six months. The primary study showed that
there was no significant benefit 5 years from treatment.
Limitation of each study- primary (2011)- there was a lack of controlled treatment
between 6 months and the 5-year study. Also, it is hypothesized that benefit is not seen after 2
years, so the study may have been done too late. The authors state that a power analysis showed
they would need 80 patients to have significant data, and although originally recruited, only 58
were used in the final study. The RCT (2003) mentioned that the physical therapy program was
not followed closely, as it was done at home. They used verbal patient confirmation that the PT
was being performed, giving room for possible non-compliance. The RCT (2009) had many
limitations. The authors stated that after week 8 the study was discontinued due to lack of
significant results. They stated that there was no exercise program in conjunction with the GTN
patches, which is a mainstay of treatment, and thus a major weakness of the study. Further
complicating the study was the use of three different dosages of GTN patches, making sample
sizes smaller and comparison more difficult.
Glyceryl trinitrate is hypothesized to induce nitric oxide release into tendon fibroblasts
leading to increased collagen synthesis in tendon. However, because of this effect, systemic
absorption can lead to side effects such as headache, dermatitis rash, and facial flushing. Review
of drug safety via Lexi-Comp Online mentions careful use of GTN in patients with
cardiovascular conditions. They remind practitioners to only leave patch in place for 10-12 hours
and to rotate sites to avoid tolerance.6
CONCLUSIONS
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The three articles reviewed here point to the conclusion that GTN transdermal patches are
efficacious in treating patient rated pain associated with lateral epicondlyitis. However, only the
study by Paoloni et al (2003) in the American Journal of Sports Medicine showed concrete
evidence, as it was the most thourough study. The 2009 Paoloni et al study in the British Journal
of Sports Medicine was not followed through past 8 weeks, but pointed to positive results with
GTN therapy if combined with PT concurrently. The prospective study by McCallum et al.
(2011) showed that there are no long term effects of GTN therapy. They did point out that a
shorter time may have better results, as a similar study with GTN and Achilles tendonitis had
efficacy at 3 years.7
Looking at these faults, further studies can be proposed to better answer the question of
GTN efficacy with lateral epicondylitis. Because there was only one RCT that was followed
through to 6 months, more trials are warranted. Also, rating patient response at 2 years instead of
at 5 years may prove that there is less pain and tenderness in the GTN group as compared with
placebo.

Chartier, GTN 10

Chartier, GTN 11
REFERENCES

1. Papadakis M, McPhee S. Upper extremity: lateral and medial epicondylosis. CURRENT
medical diagnosis and treatment. 2014; 41(1631-1632)
2. Paoloni JA, Appleyard RC, Nelson J, Murrell GA. Topical nitric oxide application in the
treatment of chronic extensor tendinosis at the elbow: A randomized, double-blinded,
placebo-controlled clinical trial. Am J Sports Med. 2003;31(6):915-920.
3. Paoloni JA, Murrell GA, Burch RM, Ang RY. Randomised, double-blind, placebocontrolled clinical trial of a new topical glyceryl trinitrate patch for chronic lateral
epicondylosis. Br J Sports Med. 2009;43(4):299-302.
4.

McCallum SD, Paoloni JA, Murrell GA. Five-year prospective comparison study of
topical glyceryl trinitrate treatment of chronic lateral epicondylosis at the elbow. Br J
Sports Med. 2011;45(5):416-420

5. Paoloni JA, Appleyard RC, Murrell GA. The Orthopaedic Research Institute-Tennis
Elbow Testing System: A modified chair pick-up test-interrater and intrarater reliability
testing and validity for monitoring lateral epicondylosis. Journal of Shoulder and Elbow
surgery. 2004 Jan-Feb;13(1):72-7.
6. Lexi-Comp
Online. http://online.lexi.com.ezproxy.pcom.edu:2048/lco/action/doc/retrieve/docid/patch
_f/7377 Nitroglycerin. Retrieved 12/16/14.
7. Paoloni JA, Murrell GA. Three-year followup study of topical glyceryl trinitrate
treatment of chronic noninsertional achilles tendinopathy. Foot Ankle Int 2007;28:1064–8

Chartier, GTN 12

